{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:19:35Z","timestamp":1791908375626,"version":"4.3.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gadoxetic acid-enhanced magnetic resonance imaging (MRI) has become a pivotal imaging modality in hepatocellular carcinoma (HCC) management, offering unique advantages owing to its hepatocyte-specific contrast properties. Its technical foundation includes optimized dynamic phase imaging and hepatobiliary phase (HBP) acquisition, which together provide functional information unattainable with conventional extracellular contrast agents. This modality enhances sensitivity in detecting HCC and enables superior characterization of focal liver lesions based on hepatocyte-specific uptake patterns. In high-risk patients with chronic liver disease, gadoxetic acid-enhanced MRI facilitates the early detection of small and early-stage HCCs, enabling timely intervention and potentially improving clinical outcomes. Beyond diagnosis, gadoxetic acid-enhanced MRI aids in predicting treatment response by evaluating tumor biological characteristics. Key imaging biomarkers include: hyperintense or heterogeneous HCC on HBP, suggesting tumor immune microenvironment; peritumoral hypointensity on HBP, suggesting microvascular invasion; and clear hypointensity on HBP with several other findings, indicating vessels encapsulating tumor clusters, characteristic of the macrotrabecular-massive HCC subtype. These biomarkers support a comprehensive evaluation of histological differentiation and biological aggressiveness. Furthermore, this modality demonstrates superior accuracy in assessing local therapy effectiveness and monitoring systemic treatment responses compared to conventional imaging. Major international hepatology societies have incorporated gadoxetic acid-enhanced MRI into their HCC diagnostic algorithms, albeit with regional differences in emphasis. Eastern guidelines (e.g., from the Japan Society of Hepatology and the Asian Pacific Association for the Study of the Liver) prioritize sensitivity, whereas Western guidelines (e.g., from the European Association for the Study of the Liver and the Liver Imaging Reporting and Data System) emphasize specificity. Despite certain limitations, including potential suboptimal arterial phase visualization, challenges in interpreting the transitional phase, higher cost, and longer examination times, gadoxetic acid-enhanced MRI remains an indispensable tool in precision oncology, enabling personalized treatment strategies and supporting optimal patient outcomes through comprehensive HCC characterization and accurate treatment monitoring.<\/jats:p>","DOI":"10.1007\/s11604-025-01870-x","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T02:51:07Z","timestamp":1757904667000},"page":"2-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Gadoxetic acid-enhanced MRI in hepatocellular carcinoma: a comprehensive review of diagnostic, surveillance, and treatment response prediction and assessment"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-7512","authenticated-orcid":false,"given":"Kumi","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukichi","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Goshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"1870_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","volume":"164","author":"MR Toh","year":"2023","unstructured":"Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PKH, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164:766\u201382. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.033.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"1870_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4\u201313. https:\/\/doi.org\/10.1002\/hep.31288.","journal-title":"Hepatology"},{"key":"1870_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(18)30010-2.","journal-title":"Lancet"},{"key":"1870_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","volume":"3","author":"SY Kim","year":"2017","unstructured":"Kim SY, An J, Lim YS, Han S, Lee JY, Byun JH, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3:456\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3147.","journal-title":"JAMA Oncol"},{"key":"1870_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1159\/000506834","volume":"9","author":"JH Yoon","year":"2020","unstructured":"Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, et al. A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development. Liver Cancer. 2020;9:503\u201317. https:\/\/doi.org\/10.1159\/000506834.","journal-title":"Liver Cancer"},{"key":"1870_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jhep.2012.01.031","volume":"57","author":"BE Van Beers","year":"2012","unstructured":"Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012;57:421\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2012.01.031.","journal-title":"J Hepatol"},{"key":"1870_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2463\/mrms.rev.2022-0100","volume":"22","author":"S Ichikawa","year":"2023","unstructured":"Ichikawa S, Goshima S. Clinical significance of liver MR imaging. Magn Reson Med Sci. 2023;22:157\u201375. https:\/\/doi.org\/10.2463\/mrms.rev.2022-0100.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS). Version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816\u201330. https:\/\/doi.org\/10.1148\/radiol.2018181494.","journal-title":"Radiology"},{"key":"1870_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1148\/radiol.14132361","volume":"272","author":"JY Choi","year":"2014","unstructured":"Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272:635\u201354. https:\/\/doi.org\/10.1148\/radiol.14132361.","journal-title":"Radiology"},{"key":"1870_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1148\/radiol.14132361","volume":"261","author":"K Sano","year":"2011","unstructured":"Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology. 2011;261:834\u201344. https:\/\/doi.org\/10.1148\/radiol.14132361.","journal-title":"Radiology"},{"key":"1870_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1148\/radiol.2020192275","volume":"296","author":"I Joo","year":"2020","unstructured":"Joo I, Kim SY, Kang TW, Kim YK, Park BJ, Lee YJ, et al. Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI: a multicenter study. Radiology. 2020;296:335\u201345. https:\/\/doi.org\/10.1148\/radiol.2020192275.","journal-title":"Radiology"},{"key":"1870_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1148\/rg.210156","volume":"42","author":"JD LeGout","year":"2022","unstructured":"LeGout JD, Bolan CW, Bowman AW, Caserta MP, Chen FK, Cox KL, et al. Focal nodular hyperplasia and focal nodular hyperplasia-like lesions. Radiographics. 2022;42:1043\u201361. https:\/\/doi.org\/10.1148\/rg.210156.","journal-title":"Radiographics"},{"key":"1870_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jmri.26768","volume":"51","author":"SS Kim","year":"2020","unstructured":"Kim SS, Kim SH, Song KD, Choi SY, Heo NH. Value of gadoxetic acid\u2010enhanced MRI and diffusion\u2010weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: a retrospective case\u2013control study. J Magn Reson Imaging. 2020;51:70\u201380. https:\/\/doi.org\/10.1002\/jmri.26768.","journal-title":"J Magn Reson Imaging"},{"key":"1870_CR14","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1440-1746.2011.06659.x","volume":"26","author":"JY Choi","year":"2011","unstructured":"Choi JY, Lee HC, Yim JH, Shim JH, Lim YS, Shin YM, et al. Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis. J Gastroenterol Hepatol. 2011;26:1004\u20139. https:\/\/doi.org\/10.1111\/j.1440-1746.2011.06659.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"1870_CR15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i2.98031","volume":"31","author":"A Urase","year":"2025","unstructured":"Urase A, Tsurusaki M, Kozuki R, Kono A, Sofue K, Ishii K. Imaging characteristics of hypervascular focal nodular hyperplasia-like lesions in patients with chronic alcoholic liver disease. World J Gastroenterol. 2025;31:98031.","journal-title":"World J Gastroenterol"},{"key":"1870_CR16","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220134","volume":"43","author":"JR Tse","year":"2023","unstructured":"Tse JR, Felker ER, Naini BV, Shen L, Shen J, Lu DSK, et al. Hepatocellular adenomas: molecular basis and multimodality imaging update. Radiographics. 2023;43:e220134. https:\/\/doi.org\/10.1148\/rg.220134.","journal-title":"Radiographics"},{"key":"1870_CR17","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/modpathol.2016.122","volume":"29","author":"G Hale","year":"2016","unstructured":"Hale G, Liu X, Hu J, Xu Z, Che L, Solomon D, et al. Correlation of exon 3 \u03b2-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma. Mod Pathol. 2016;29:1370\u201380. https:\/\/doi.org\/10.1038\/modpathol.2016.122.","journal-title":"Mod Pathol"},{"key":"1870_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00261-019-02328-1","volume":"45","author":"T Teo","year":"2020","unstructured":"Teo T, Chawla A. The cloud sign of mass-forming intrahepatic cholangiocarcinoma. Abdom Radiol (NY). 2020;45:237\u20138. https:\/\/doi.org\/10.1007\/s00261-019-02328-1.","journal-title":"Abdom Radiol (NY)"},{"key":"1870_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1148\/radiol.2018171187","volume":"288","author":"I Joo","year":"2018","unstructured":"Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology. 2018;288:7\u201313. https:\/\/doi.org\/10.1148\/radiol.2018171187.","journal-title":"Radiology"},{"key":"1870_CR20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1148\/rg.220056","volume":"42","author":"K Ozaki","year":"2022","unstructured":"Ozaki K, Higuchi S, Kimura H, Gabata T. Liver metastases: correlation between imaging features and pathomolecular environments. Radiographics. 2022;42:1994\u20132013. https:\/\/doi.org\/10.1148\/rg.220056.","journal-title":"Radiographics"},{"key":"1870_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17998\/jlc.2025.02.16","volume":"25","author":"DH Lee","year":"2025","unstructured":"Lee DH. Recent advances and issues in imaging modalities for hepatocellular carcinoma surveillance. J Liver Cancer. 2025;25:31\u201340. https:\/\/doi.org\/10.17998\/jlc.2025.02.16.","journal-title":"J Liver Cancer"},{"key":"1870_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00261-015-0592-8","volume":"41","author":"RF Hanna","year":"2016","unstructured":"Hanna RF, Miloushev VZ, Tang A, Finklestone LA, Brejt SZ, Sandhu RS, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol. 2016;41:71\u201390. https:\/\/doi.org\/10.1007\/s00261-015-0592-8.","journal-title":"Abdom Radiol"},{"key":"1870_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024602","volume":"100","author":"J Wang","year":"2021","unstructured":"Wang J, Ye X, Li J, He S. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: a meta-analysis. Medicine. 2021;100:e24602. https:\/\/doi.org\/10.1097\/MD.0000000000024602.","journal-title":"Medicine"},{"key":"1870_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001157","volume":"94","author":"F Ye","year":"2015","unstructured":"Ye F, Liu J, Ouyang H. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Med (Baltim). 2015;94:e1157. https:\/\/doi.org\/10.1097\/MD.0000000000001157.","journal-title":"Med (Baltim)"},{"key":"1870_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00535-015-1097-5","volume":"51","author":"M Tsurusaki","year":"2016","unstructured":"Tsurusaki M, Sofue K, Isoda H, Okada M, Kitajima K, Murakami T. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol. 2016;51:71\u20139. https:\/\/doi.org\/10.1007\/s00535-015-1097-5.","journal-title":"J Gastroenterol"},{"key":"1870_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hep.29487","volume":"67","author":"LR Roberts","year":"2018","unstructured":"Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology. 2018;67:401\u201321. https:\/\/doi.org\/10.1002\/hep.29487.","journal-title":"Hepatology"},{"key":"1870_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1148\/radiol.14140141","volume":"274","author":"DH Lee","year":"2015","unstructured":"Lee DH, Lee JM, Baek JH, Shin CI, Han JK, Choi BI. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Radiology. 2015;274:149\u201360. https:\/\/doi.org\/10.1148\/radiol.14140141.","journal-title":"Radiology"},{"key":"1870_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1148\/radiol.2017162080","volume":"285","author":"BR Kim","year":"2017","unstructured":"Kim BR, Lee JM, Lee DH, Yoon JH, Hur BY, Suh KS, et al. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging versus multidetector CT in the detection of dysplastic nodules and early hepatocellular carcinoma. Radiology. 2017;285:134\u201346. https:\/\/doi.org\/10.1148\/radiol.2017162080.","journal-title":"Radiology"},{"key":"1870_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11604-012-0120-5","volume":"30","author":"M Takechi","year":"2012","unstructured":"Takechi M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, et al. Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Jpn J Radiol. 2012;30:743\u201351. https:\/\/doi.org\/10.1007\/s11604-012-0120-5.","journal-title":"Jpn J Radiol"},{"key":"1870_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.acra.2020.08.031","volume":"29","author":"TH Kim","year":"2022","unstructured":"Kim TH, Woo S, Han S, Suh CH, Do RKG, Lee JM. Risk factors for hypervascularization in hepatobiliary phase hypointense nodules without arterial phase hyperenhancement: a systematic review and meta-analysis. Acad Radiol. 2022;29:198\u2013210. https:\/\/doi.org\/10.1016\/j.acra.2020.08.031.","journal-title":"Acad Radiol"},{"key":"1870_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12029-017-9952-7","volume":"49","author":"C Briani","year":"2018","unstructured":"Briani C, Di Pietropaolo M, Marignani M, Carbonetti F, Begini P, David V, et al. Non-hypervascular hypointense nodules at gadoxetic acid MRI: hepatocellular carcinoma risk assessment with emphasis on the role of diffusion-weighted imaging. J Gastrointest Cancer. 2018;49:302\u201310. https:\/\/doi.org\/10.1007\/s12029-017-9952-7.","journal-title":"J Gastrointest Cancer"},{"key":"1870_CR32","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s00330-019-06499-9","volume":"30","author":"TH Kim","year":"2020","unstructured":"Kim TH, Woo S, Han S, Suh CH, Lee DH, Lee JM. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. Eur Radiol. 2020;30:1624\u201333. https:\/\/doi.org\/10.1007\/s00330-019-06499-9.","journal-title":"Eur Radiol"},{"key":"1870_CR33","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.clinthera.2017.03.006","volume":"39","author":"A Nishie","year":"2017","unstructured":"Nishie A, Goshima S, Haradome H, Hatano E, Imai Y, Kudo M, et al. Cost-effectiveness of EOB-MRI for hepatocellular carcinoma in Japan. Clin Ther. 2017;39:738-750.e4. https:\/\/doi.org\/10.1016\/j.clinthera.2017.03.006.","journal-title":"Clin Ther"},{"key":"1870_CR34","doi-asserted-by":"publisher","first-page":"W63","DOI":"10.2214\/AJR.17.18300","volume":"210","author":"CH Suh","year":"2018","unstructured":"Suh CH, Kim KW, Park SH, Kim SY, Woo DC, Shin S, et al. Performing gadoxetic acid-enhanced MRI after CT for guiding curative treatment of early-stage hepatocellular carcinoma: a cost-effectiveness analysis. AJR Am J Roentgenol. 2018;210:W63\u20139. https:\/\/doi.org\/10.2214\/AJR.17.18300.","journal-title":"AJR Am J Roentgenol"},{"key":"1870_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2463\/mrms.mp.2022-0111","volume":"23","author":"K Kiso","year":"2024","unstructured":"Kiso K, Tsuboyama T, Onishi H, Ogawa K, Nakamoto A, Tatsumi M, et al. Effect of deep learning reconstruction on respiratory-triggered T2-weighted MR imaging of the liver: a comparison between the single-shot fast spin-echo and fast spin-echo sequences. Magn Reson Med Sci. 2024;23:214\u201324. https:\/\/doi.org\/10.2463\/mrms.mp.2022-0111.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2463\/mrms.rev.2022-0107","volume":"22","author":"M Obara","year":"2023","unstructured":"Obara M, Kwon J, Yoneyama M, Ueda Y, Cauteren MV. Technical advancements in abdominal diffusion-weighted imaging. Magn Reson Med Sci. 2023;22:191\u2013208. https:\/\/doi.org\/10.2463\/mrms.rev.2022-0107.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2463\/mrms.mp.2022-0137","volume":"23","author":"K Ihara","year":"2024","unstructured":"Ihara K, Onoda H, Tanabe M, Iida E, Ueda T, Kobayashi T, et al. Breath-hold high-resolution T1-weighted gradient echo liver MR imaging with compressed sensing obtained during the gadoxetic acid-enhanced hepatobiliary phase: image quality and lesion visibility compared with a standard T1-weighted sequence. Magn Reson Med Sci. 2024;23:146\u201352. https:\/\/doi.org\/10.2463\/mrms.mp.2022-0137.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2463\/mrms.mp.2022-0041","volume":"22","author":"S Kondo","year":"2023","unstructured":"Kondo S, Nakamura Y, Higaki T, Nishihara T, Takizawa M, Shirai T, et al. Utility of wavelet denoising with geometry factor weighting for gadoxetic acid-enhanced hepatobiliary-phase MR imaging. Magn Reson Med Sci. 2023;22:241\u201352. https:\/\/doi.org\/10.2463\/mrms.mp.2022-0041.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2463\/mrms.rev.2022-0114","volume":"22","author":"H Kabasawa","year":"2023","unstructured":"Kabasawa H, Kiryu S. Pulse sequences and reconstruction in fast MR imaging of the liver. Magn Reson Med Sci. 2023;22:176\u201390. https:\/\/doi.org\/10.2463\/mrms.rev.2022-0114.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2463\/mrms.rev.2022-0102","volume":"22","author":"T Nakaura","year":"2023","unstructured":"Nakaura T, Kobayashi N, Yoshida N, Shiraishi K, Uetani H, Nagayama Y, et al. Update on the use of artificial intelligence in hepatobiliary MR imaging. Magn Reson Med Sci. 2023;22:147\u201356. https:\/\/doi.org\/10.2463\/mrms.rev.2022-0102.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2463\/mrms.mp.2021-0087","volume":"22","author":"N Ohno","year":"2023","unstructured":"Ohno N, Yoshida K, Ueda Y, Makino Y, Miyati T, Gabata T, et al. Diffusion-weighted imaging of the abdomen during a single breath-hold using simultaneous-multislice echo-planar imaging. Magn Reson Med Sci. 2023;22:253\u201362. https:\/\/doi.org\/10.2463\/mrms.mp.2021-0087.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goaf045","volume":"13","author":"N Polpichai","year":"2025","unstructured":"Polpichai N, Maneenil C, Danpanichkul P, Rattananukrom C, Choudhury A, Wong YJ, et al. Current and new strategies for hepatocellular carcinoma surveillance. Gastroenterol Rep. 2025;13:goaf045. https:\/\/doi.org\/10.1093\/gastro\/goaf045.","journal-title":"Gastroenterol Rep"},{"key":"1870_CR43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1148\/radiol.14132362","volume":"273","author":"JY Choi","year":"2014","unstructured":"Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273:30\u201350. https:\/\/doi.org\/10.1148\/radiol.14132362.","journal-title":"Radiology"},{"key":"1870_CR44","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1259\/bjr\/94924398","volume":"85","author":"N Griffin","year":"2012","unstructured":"Griffin N, Addley H, Sala E, Shaw AS, Grant LA, Eldaly H, et al. Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI? Br J Radiol. 2012;85:736\u201344. https:\/\/doi.org\/10.1259\/bjr\/94924398.","journal-title":"Br J Radiol"},{"key":"1870_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000513704","volume":"10","author":"SB Hong","year":"2021","unstructured":"Hong SB, Choi SH, Kim SY, Shim JH, Lee SS, Byun JH, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10:94\u2013106. https:\/\/doi.org\/10.1159\/000513704.","journal-title":"Liver Cancer"},{"key":"1870_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.907076","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. https:\/\/doi.org\/10.3389\/fonc.2022.907076.","journal-title":"Front Oncol"},{"key":"1870_CR47","doi-asserted-by":"publisher","first-page":"153303382312127","DOI":"10.1177\/15330338231212726","volume":"22","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Wang K, Wang YR, Xiang YJ, Liu ZH, Feng JK, et al. Preoperative and prognostic prediction of microvascular invasion in hepatocellular carcinoma: a review based on artificial intelligence. Technol Cancer Res Treat. 2023;22:15330338231212726. https:\/\/doi.org\/10.1177\/15330338231212726.","journal-title":"Technol Cancer Res Treat"},{"key":"1870_CR48","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ejrad.2015.03.002","volume":"84","author":"JH Min","year":"2015","unstructured":"Min JH, Kim YK, Lim S, Jeong WK, Choi D, Lee WJ. Prediction of microvascular invasion of hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging: impact of intra-tumoral fat detected on chemical-shift images. Eur J Radiol. 2015;84:1036\u201343. https:\/\/doi.org\/10.1016\/j.ejrad.2015.03.002.","journal-title":"Eur J Radiol"},{"key":"1870_CR49","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.21873\/anticanres.12322","volume":"38","author":"K Imai","year":"2018","unstructured":"Imai K, Yamashita YI, Yusa T, Nakao Y, Itoyama R, Nakagawa S, et al. Microvascular invasion in small-sized hepatocellular carcinoma: significance for outcomes following hepatectomy and radiofrequency ablation. Anticancer Res. 2018;38:1053\u201360. https:\/\/doi.org\/10.21873\/anticanres.12322.","journal-title":"Anticancer Res"},{"key":"1870_CR50","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1245\/s10434-021-09901-3","volume":"28","author":"S Bai","year":"2021","unstructured":"Bai S, Yang P, Xie Z, Li J, Lei Z, Xia Y, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis B virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28:8174\u201385. https:\/\/doi.org\/10.1245\/s10434-021-09901-3.","journal-title":"Ann Surg Oncol"},{"key":"1870_CR51","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1148\/radiol.11110817","volume":"262","author":"ZW Peng","year":"2012","unstructured":"Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012;262:1022\u201333. https:\/\/doi.org\/10.1148\/radiol.11110817.","journal-title":"Radiology"},{"key":"1870_CR52","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jhep.2011.05.020","volume":"56","author":"JH Wang","year":"2012","unstructured":"Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early\/early stage hepatocellular carcinoma. J Hepatol. 2012;56:412\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2011.05.020.","journal-title":"J Hepatol"},{"key":"1870_CR53","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.surg.2018.09.016","volume":"165","author":"P Yang","year":"2019","unstructured":"Yang P, Si A, Yang J, Cheng Z, Wang K, Li J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. Surgery. 2019;165:721\u201330. https:\/\/doi.org\/10.1016\/j.surg.2018.09.016.","journal-title":"Surgery"},{"key":"1870_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00261-018-1768-9","volume":"44","author":"SJ Ahn","year":"2019","unstructured":"Ahn SJ, Kim JH, Park SJ, Kim ST, Han JK. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis. Abdom Radiol. 2019;44:539\u201348. https:\/\/doi.org\/10.1007\/s00261-018-1768-9.","journal-title":"Abdom Radiol"},{"key":"1870_CR55","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1148\/radiol.2017162846","volume":"286","author":"SY Choi","year":"2018","unstructured":"Choi SY, Kim SH, Park CK, Min JH, Lee JE, Choi YH, et al. Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study. Radiology. 2018;286:897\u2013908. https:\/\/doi.org\/10.1148\/radiol.2017162846.","journal-title":"Radiology"},{"key":"1870_CR56","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/SLA.0000000000003268","volume":"273","author":"S Lee","year":"2021","unstructured":"Lee S, Kang TW, Song KD, Lee MW, Rhim H, Lim HK, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273:564\u201371. https:\/\/doi.org\/10.1097\/SLA.0000000000003268.","journal-title":"Ann Surg"},{"key":"1870_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.868429","volume":"12","author":"MC Wei","year":"2022","unstructured":"Wei MC, Zhang YJ, Chen MS, Chen Y, Lau WY, Peng ZW. Adjuvant sorafenib following radiofrequency ablation for early-stage recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Front Oncol. 2022;12:868429. https:\/\/doi.org\/10.3389\/fonc.2022.868429.","journal-title":"Front Oncol"},{"key":"1870_CR58","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3389\/fonc.2019.01065","volume":"9","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Zhu X, Wang H, Dong D, Gao S, Zhu X, et al. Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion. Front Oncol. 2019;9:1065. https:\/\/doi.org\/10.3389\/fonc.2019.01065.","journal-title":"Front Oncol"},{"key":"1870_CR59","doi-asserted-by":"publisher","DOI":"10.12771\/emj.2024.e58","volume":"47","author":"W Chung","year":"2024","unstructured":"Chung W, Kim H. The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review. EWHA Med J. 2024;47:e58. https:\/\/doi.org\/10.12771\/emj.2024.e58.","journal-title":"EWHA Med J"},{"key":"1870_CR60","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/jmri.29187","volume":"60","author":"Q Qu","year":"2024","unstructured":"Qu Q, Liu Z, Lu M, Xu L, Zhang J, Liu M, et al. Preoperative gadoxetic acid-enhanced MRI features for evaluation of vessels encapsulating tumor clusters and microvascular invasion in hepatocellular carcinoma: creating nomograms for risk assessment. J Magn Reson Imaging. 2024;60:1094\u2013110. https:\/\/doi.org\/10.1002\/jmri.29187.","journal-title":"J Magn Reson Imaging"},{"key":"1870_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2025.111936","volume":"183","author":"XP Meng","year":"2025","unstructured":"Meng XP, Qu X, Guo YX, Qi X, Bian L, Wu D, et al. Validation of proposed imaging criteria for estimating vessels encapsulating tumor clusters in hepatocellular carcinoma at CT and gadoxetic acid-enhanced MRI. Eur J Radiol. 2025;183:111936. https:\/\/doi.org\/10.1016\/j.ejrad.2025.111936.","journal-title":"Eur J Radiol"},{"key":"1870_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1148\/radiol.2021203614","volume":"300","author":"Z Feng","year":"2021","unstructured":"Feng Z, Li H, Zhao H, Jiang Y, Liu Q, Chen Q, et al. Preoperative CT for characterization of aggressive macrotrabecular-massive subtype and vessels that encapsulate tumor clusters pattern in hepatocellular carcinoma. Radiology. 2021;300:219\u201329. https:\/\/doi.org\/10.1148\/radiol.2021203614.","journal-title":"Radiology"},{"key":"1870_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215428","volume":"14","author":"CW Huang","year":"2022","unstructured":"Huang CW, Lin SE, Huang SF, Yu MC, Tang JH, Tsai CN, et al. The vessels that encapsulate tumor clusters (VETC) pattern is a poor prognosis factor in patients with hepatocellular carcinoma: an analysis of microvessel density. Cancers (Basel). 2022;14:5428. https:\/\/doi.org\/10.3390\/cancers14215428.","journal-title":"Cancers (Basel)"},{"key":"1870_CR64","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1007\/s00432-022-04323-4","volume":"149","author":"JH Wang","year":"2023","unstructured":"Wang JH, Li XS, Tang HS, Fang RY, Song JJ, Feng YL, et al. Vessels that encapsulate tumor clusters (VETC) pattern predicts the efficacy of adjuvant TACE in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149:4163\u201372. https:\/\/doi.org\/10.1007\/s00432-022-04323-4.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1870_CR65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/JHC.S395903","volume":"10","author":"C Lin","year":"2023","unstructured":"Lin C, He Y, Liu M, Wu A, Zhang J, Li S, et al. Vessels that encapsulate tumor clusters (VETC) predict cTACE response in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:383\u201397. https:\/\/doi.org\/10.2147\/JHC.S395903.","journal-title":"J Hepatocell Carcinoma"},{"key":"1870_CR66","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jhep.2014.06.008","volume":"61","author":"A Ueno","year":"2014","unstructured":"Ueno A, Masugi Y, Yamazaki K, Komuta M, Effendi K, Tanami Y, et al. OATP1B3 expression is strongly associated with Wnt\/\u03b2-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61:1080\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2014.06.008.","journal-title":"J Hepatol"},{"key":"1870_CR67","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1148\/radiol.14141315","volume":"275","author":"A Kitao","year":"2015","unstructured":"Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Sanada J, et al. Hepatocellular carcinoma with \u03b2-catenin mutation: imaging and pathologic characteristics. Radiology. 2015;275:708\u201317. https:\/\/doi.org\/10.1148\/radiol.14141315.","journal-title":"Radiology"},{"key":"1870_CR68","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1007\/s00330-022-08643-4","volume":"32","author":"JK Yoon","year":"2022","unstructured":"Yoon JK, Choi JY, Rhee H, Park YN. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Eur Radiol. 2022;32:5119\u201333. https:\/\/doi.org\/10.1007\/s00330-022-08643-4.","journal-title":"Eur Radiol"},{"key":"1870_CR69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejrad.2017.02.004","volume":"89","author":"JW Kim","year":"2017","unstructured":"Kim JW, Lee CH, Park YS, Seo TS, Song MG, Kim JH, et al. The value of paradoxical uptake of hepatocellular carcinoma on the hepatobiliary phase of gadoxetic acid-enhanced liver magnetic resonance imaging for the prediction of lipiodol uptake after transcatheter arterial chemoembolization. Eur J Radiol. 2017;89:169\u201376. https:\/\/doi.org\/10.1016\/j.ejrad.2017.02.004.","journal-title":"Eur J Radiol"},{"key":"1870_CR70","doi-asserted-by":"publisher","first-page":"744","DOI":"10.2214\/AJR.13.10848","volume":"202","author":"H Ishimaru","year":"2014","unstructured":"Ishimaru H, Nakashima K, Sakugawa T, Sakamoto A, Matsuoka Y, Ashizawa K, et al. Local recurrence after chemoembolization of hepatocellular carcinoma: uptake of gadoxetic acid as a new prognostic factor. AJR Am J Roentgenol. 2014;202:744\u201351. https:\/\/doi.org\/10.2214\/AJR.13.10848.","journal-title":"AJR Am J Roentgenol"},{"key":"1870_CR71","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000518048","volume":"10","author":"T Aoki","year":"2021","unstructured":"Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, et al. Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of anti-PD-1\/PD-L1 monotherapy for unresectable hepatocellular carcinoma. Liver Cancer. 2021;10:615\u201328. https:\/\/doi.org\/10.1159\/000518048.","journal-title":"Liver Cancer"},{"key":"1870_CR72","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/cancers14030827","volume":"14","author":"R Sasaki","year":"2022","unstructured":"Sasaki R, Nagata K, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, et al. Evaluating the role of hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in predicting treatment impact of lenvatinib and atezolizumab plus bevacizumab on unresectable hepatocellular carcinoma. Cancers. 2022;14:827. https:\/\/doi.org\/10.3390\/cancers14030827.","journal-title":"Cancers"},{"key":"1870_CR73","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000542099","volume":"14","author":"E Ueshima","year":"2024","unstructured":"Ueshima E, Sofue K, Kodama T, Yamamoto S, Komatsu M, Komatsu S, et al. Gadoxetic acid-enhanced magnetic resonance imaging features can predict immune-excluded phenotype of hepatocellular carcinoma. Liver Cancer. 2024;14:271\u201385. https:\/\/doi.org\/10.1159\/000542099.","journal-title":"Liver Cancer"},{"key":"1870_CR74","doi-asserted-by":"publisher","first-page":"24076","DOI":"10.1038\/s41598-021-01839-6","volume":"11","author":"JY Lee","year":"2021","unstructured":"Lee JY, Lee BC, Kim HO, Heo SH, Shin SS, Jeong YY. Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma. Sci Rep. 2021;11:24076. https:\/\/doi.org\/10.1038\/s41598-021-01839-6.","journal-title":"Sci Rep"},{"issue":"3","key":"1870_CR75","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"1870_CR76","unstructured":"WHO handbook for reporting results of cancer treatment (1979) Geneva: World Health Organization. Offset Publication No. 48. Accessed 1 Jul 2022"},{"key":"1870_CR77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132.","journal-title":"Semin Liver Dis"},{"key":"1870_CR78","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2463\/mrms.rev.2022-0118","volume":"22","author":"Y Tsujita","year":"2023","unstructured":"Tsujita Y, Sofue K, Ueshima E, Ueno Y, Hori M, Tsurusaki M, et al. Evaluation and prediction of treatment response for hepatocellular carcinoma. Magn Reson Med Sci. 2023;22:209\u201320. https:\/\/doi.org\/10.2463\/mrms.rev.2022-0118.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174432","volume":"13","author":"YJ Huh","year":"2021","unstructured":"Huh YJ, Kim DH, Kim B, Choi JI, Rha SE. Per-feature accuracy of liver imaging reporting and data system locoregional treatment response algorithm: a systematic review and meta-analysis. Cancers (Basel). 2021;13:4432. https:\/\/doi.org\/10.3390\/cancers13174432.","journal-title":"Cancers (Basel)"},{"key":"1870_CR80","doi-asserted-by":"publisher","first-page":"469097","DOI":"10.1155\/2013\/469097","volume":"2013","author":"V Granata","year":"2013","unstructured":"Granata V, Petrillo M, Fusco R, Setola SV, de Lutio di Castelguidone E, Catalano O, et al. Surveillance of HCC patients after liver RFA: Role of MRI with hepatospecific contrast versus three-phase CT scan-experience of high volume oncologic institute. Gastroenterol Res Pract. 2013;2013:469097. https:\/\/doi.org\/10.1155\/2013\/469097.","journal-title":"Gastroenterol Res Pract"},{"key":"1870_CR81","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"1870_CR82","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2468-1253(24)00267-X","volume":"10","author":"SO Dudzinski","year":"2025","unstructured":"Dudzinski SO, Newman NB, McIntyre J, Engineer R, Sanford NN, Wo JY, et al. Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2025;10:387\u201398. https:\/\/doi.org\/10.1016\/S2468-1253(24)00267-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1870_CR83","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijrobp.2012.08.043","volume":"87","author":"J Klein","year":"2013","unstructured":"Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013;87:22\u201332. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.08.043.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1870_CR84","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/17474124.2020.1744434","volume":"14","author":"T Kimura","year":"2020","unstructured":"Kimura T, Doi Y, Takahashi S, Kubo K, Imano N, Takeuchi Y, et al. An overview of stereotactic body radiation therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2020;14:271\u20139. https:\/\/doi.org\/10.1080\/17474124.2020.1744434.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1870_CR85","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ijrobp.2013.10.045","volume":"88","author":"N Sanuki","year":"2014","unstructured":"Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, et al. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA. Int J Radiat Oncol Biol Phys. 2014;88:306\u201311. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.10.045.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1870_CR86","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ijrobp.2009.02.030","volume":"76","author":"S Sugahara","year":"2010","unstructured":"Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010;76:460\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.030.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1870_CR87","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.crad.2023.06.005","volume":"78","author":"HM Kwok","year":"2023","unstructured":"Kwok HM, Chau CM, Lee HCH, Wong T, Chan HF, Luk WH, et al. Gadoxetic acid in hepatocellular carcinoma and liver metastases: pearls and pitfalls. Clin Radiol. 2023;78:715\u201323. https:\/\/doi.org\/10.1016\/j.crad.2023.06.005.","journal-title":"Clin Radiol"},{"key":"1870_CR88","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11604-020-01052-x","volume":"39","author":"M Tsurusaki","year":"2021","unstructured":"Tsurusaki M, Sofue K, Onishi H, Goshima S, Higaki A, Isoda H, et al. Predictive factors of truncation artifacts in the arterial phase of Gd-EOB-DTPA-enhanced MRI: a nationwide multicenter study. Jpn J Radiol. 2021;39:165\u201377. https:\/\/doi.org\/10.1007\/s11604-020-01052-x.","journal-title":"Jpn J Radiol"},{"key":"1870_CR89","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00261-016-0948-8","volume":"42","author":"NS Ikram","year":"2017","unstructured":"Ikram NS, Yee J, Weinstein S, Yeh BM, Corvera CU, Monto A, et al. Multiple arterial phase MRI of arterial hypervascular hepatic lesions: improved arterial phase capture and lesion enhancement. Abdom Radiol. 2017;42:870\u20136. https:\/\/doi.org\/10.1007\/s00261-016-0948-8.","journal-title":"Abdom Radiol"},{"key":"1870_CR90","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1007\/s00261-023-04096-5","volume":"49","author":"J Jiang","year":"2024","unstructured":"Jiang J, Yang D, Yang Z, Han X, Xu L, Wang Y, et al. The timing phase affected the inconsistency of APHE subtypes of liver observations in patients at risk for HCC on the multi-hepatic arterial phase imaging. Abdom Radiol. 2024;49:1092\u2013102. https:\/\/doi.org\/10.1007\/s00261-023-04096-5.","journal-title":"Abdom Radiol"},{"key":"1870_CR91","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2463\/mrms.mp.2021-0143","volume":"22","author":"S Ichikawa","year":"2023","unstructured":"Ichikawa S, Motosugi U, Wakayama T, Morisaka H, Funayama S, Tamada D, et al. An intra-individual comparison between free-breathing dynamic MR imaging of the liver using stack-of-stars acquisition and the breath-holding method using Cartesian sampling or view-sharing. Magn Reson Med Sci. 2023;22:221\u201331. https:\/\/doi.org\/10.2463\/mrms.mp.2021-0143.","journal-title":"Magn Reson Med Sci"},{"key":"1870_CR92","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1038\/s41598-023-33048-8","volume":"13","author":"E Nishioka","year":"2023","unstructured":"Nishioka E, Sofue K, Maruyama K, Ueshima E, Ueno Y, Tsurusaki M, et al. Improved diagnosis of histological capsule in hepatocallular carcinoma by using nonenhancing capsule appearance in addition to enhancing capsule appearance in gadoxetic acid-enhanced MRI. Sci Rep. 2023;13:6113. https:\/\/doi.org\/10.1038\/s41598-023-33048-8.","journal-title":"Sci Rep"},{"key":"1870_CR93","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00330-015-3798-9","volume":"26","author":"B Kim","year":"2016","unstructured":"Kim B, Byun JH, Kim HJ, Won HJ, Kim SY, Shin YM, et al. Enhancement patterns and pseudo-washout of hepatic haemangiomas on gadoxetate disodium-enhanced liver MRI. Eur Radiol. 2016;26:191\u20138. https:\/\/doi.org\/10.1007\/s00330-015-3798-9.","journal-title":"Eur Radiol"},{"key":"1870_CR94","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/jmri.26540","volume":"49","author":"V Chernyak","year":"2019","unstructured":"Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS). J Magn Reson Imaging. 2019;49:1236\u201352. https:\/\/doi.org\/10.1002\/jmri.26540.","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"1870_CR95","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1148\/radiol.2019182867","volume":"292","author":"SM Lee","year":"2019","unstructured":"Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH. LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology. 2019;292(3):655\u201363. https:\/\/doi.org\/10.1148\/radiol.2019182867.","journal-title":"Radiology"},{"key":"1870_CR96","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Hepatol"},{"key":"1870_CR97","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1007\/s00330-020-06881-y","volume":"30","author":"SK Jeon","year":"2020","unstructured":"Jeon SK, Lee JM, Joo I, Yoo J, Park JY. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol. 2020;30:4762\u201371. https:\/\/doi.org\/10.1007\/s00330-020-06881-y.","journal-title":"Eur Radiol"},{"key":"1870_CR98","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233114","volume":"311","author":"JH Yoon","year":"2024","unstructured":"Yoon JH, Kim YK, Kim JW, Chang W, Choi JI, Park BJ, et al. Comparison of four diagnostic guidelines for hepatocellular carcinoma using gadoxetic acid-enhanced liver MRI. Radiology. 2024;311:e233114. https:\/\/doi.org\/10.1148\/radiol.233114.","journal-title":"Radiology"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01870-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-025-01870-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01870-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:33:46Z","timestamp":1767591226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-025-01870-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1870"],"URL":"https:\/\/doi.org\/10.1007\/s11604-025-01870-x","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the ethical standards of the IRB and with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}